Citius Oncology (CTOR) Other Non-Current Assets (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Other Non-Current Assets of $71.3 million for Q1 2026, down 2.89% year-over-year from $73.4 million in Q1 2025, and down 2.13% quarter-over-quarter from $72.8 million in Q4 2025.
Citius Oncology (CTOR) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Other Non-Current Assets for 4 consecutive years, with $71.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 2.89% year-over-year to $71.3 million; the TTM figure through Mar 2026 stood at $71.3 million (down 2.89% YoY), while the FY2025 annual figure was $73.4 million, changed 0.0% from the prior year.
- Other Non-Current Assets declined to $71.3 million in Q1 2026 per CTOR's latest filing, from $72.8 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $73.4 million in Q3 2024 and bottomed at $40.0 million in Q3 2023.
- Historically, Other Non-Current Assets has averaged $68.9 million across 4 years, with a median of $73.4 million in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 83.5% — and 2026, when it declined 2.89%.
- Citius Oncology's Other Non-Current Assets stood at $40.0 million in 2023, then surged by 83.5% to $73.4 million in 2024, then slipped by 0.78% to $72.8 million in 2025, then dropped by 2.13% to $71.3 million in 2026.
- Business Quant data shows CTOR's Other Non-Current Assets at $71.3 million in Q1 2026, $72.8 million in Q4 2025, and $73.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 13.00 Mn |
| 10 | Citius Oncology | 81.99 Mn | 81.99 Mn | 1.00 Mn | 69.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71.28 Mn |
| Dec 31, 2025 | 72.83 Mn |
| Sep 30, 2025 | 73.40 Mn |
| Jun 30, 2025 | 73.40 Mn |
| Mar 31, 2025 | 73.40 Mn |
| Dec 31, 2024 | 73.40 Mn |
| Sep 30, 2024 | 73.40 Mn |
| Sep 30, 2023 | 40.00 Mn |